NEWPORT NEWS, Va., Nov. 30, 2011 /PRNewswire/ -- According to a new study, Breast-Specific Gamma Imaging (BSGI), also known as Molecular Breast Imaging (MBI), can provide critical information in the initial diagnostic workup and surgical planning for patients with newly diagnosed breast cancer. Adding BSGI/MBI to conventional imaging (CI), namely mammography and ultrasound, enhances pre-surgical planning. These findings will be presented at the 2011 Radiological Society of North America (RSNA) annual meeting to be held in Chicago, Nov. 27 through Dec. 2, 2011.
In a retrospective review of records at Scripps Clinic (San Diego, Calif.), BSGI/MBI confirmed, clarified or added to findings of conventional imaging in 75 percent of patients. BSGI/MBI identified an additional lesion or significantly changed management in 20 percent of cases. BSGI was unhelpful or led to an additional nine biopsies or work-up in 25 percent of patients. The study concludes that BSGI/MBI was found to be cost-effective, well-tolerated, and was a reasonably sensitive and specific adjunct modality for enhancing pre-surgical planning for patients with newly diagnosed breast cancer, especially in relatively young female patients with dense breast tissue. For this study BSGI/MBI was conducted with a high-resolution gamma camera, the Dilon 6800®.
"Based on our review of our first year's experience with breast cancer patients who had BSGI prior to undergoing cancer treatment surgery, we have a better understanding of the modality's strengths and limitations," said Marie Tartar, M.D., of Scripps Health.
"Like all breast imaging modalities, BSGI will not identify all cancers. However, we have found in selected patients needing further evaluation for persistent questions after conventional breast imaging work-up (mammogram and/or ultrasound), BSGI can be useful and may be the first modality to indicate the presence of a breast cancer. Based on our results, BSGI seems t
|SOURCE Dilon Diagnostics|
Copyright©2010 PR Newswire.
All rights reserved